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Abstract: A male intravenous drug abuser who was infected with hepatitis B and C, presented 
with a slowly progressive hemiplegia. Contrast enhanced computerized tomography of the head 
showed a solitary ring-enhanced mass with surrounding edema. Clinically brain tumor was 
suspected but a brain biopsy conﬁ  rmed cerebral toxoplasmosis. An HIV test was not consid-
ered until the result of brain biopsy. He also had lymphopenia and positive serum toxoplasma 
antibody. His subsequent HIV test was positive. He deteriorated after a brain biopsy. Empirical 
antitoxoplasma treatment is recommended in HIV-positive patients with ring-enhanced lesions 
with surrounding edema and with positive toxoplasma serology. Cerebral toxoplasmosis is still 
the commonest cerebral opportunistic infection in HIV-infected patients even though the inci-
dence has declined with the use of antiretroviral therapy. It is often diagnosed in those patients 
as an initial presentation of HIV infection or in those who failed to attend for disease monitoring. 
Clinical features and differential diagnosis of cerebral toxoplasmosis in immunocompromised 
patients are discussed.
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Case report
In May 2005, a 45-year-old ex-intravenous drug abuser with a suspected brain 
tumor was transferred by a consultant physician at a District General Hospital to a 
neurosurgical unit at a teaching hospital. His main complaints were fever, headache, 
speech impediment, and blurring of vision. On examination the patient was conscious 
and had left sided 3 rd nerve palsy. Fundi were normal. He subsequently slowly devel-
oped a dense right hemiplegia. Investigations revealed hemoglobin 11.8 gm/l, white cell 
count 3.9 × 109/l with lymphocyte count of 0.6, platelets 174 and positive hepatitis B 
surface antigen and hepatitis C PCR. Chest radiograph was normal. Contrast-enhanced 
computerized tomography (CT) of the head showed a solitary ring enhanced mass 
in the mesenceph with surrounding edema (Figure 1). Clinically a brain tumor was 
suspected, but stereotactic brain biopsy revealed numerous tachyzoites conﬁ  rming 
cerebral toxoplasmosis (CTx) (Figure 2).
An HIV antibody test was positive with CD4 count of less than 10 cells/mm3 and 
HIV RNA (viral load) level of 2.2 millions copies/ml. Toxoplasma antibody dye test 
was positive at 64 iu/ml. Toxoplasma IgM antibody was negative. After brain biopsy 
he deteriorated but a repeat CT scan did not reveal any intra cerebral bleeding. He was 
treated with antitoxoplasma and antiretroviral therapy and was able to walk with an 
aid of stick in July 2005. In December 2005 his HIV RNA level became undetectable 
and CD4 count was 78. No further follow up was possible as the patient voluntarily 
returned to Portugal in February 2006.
Discussion
Cerebral toxoplasmosis is almost always due to reactivation of latent infection and 
typically occurs in patients with CD4 count of less than 100 cells/mm3. The major International Journal of General Medicine 2009:2 74
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Figure 1 Computed tomography scan showing ring-enhanced mass with surrounding 
edema.
clinical features of CTx include headache, hemipare-
sis, speech disturbances, cerebellar dysfunction, cranial 
nerve palsies, and sensory loss.1 It can rarely present with 
movement disorders.2 Our patient presented with headache, 
dysphasia and subacute onset of hemiplegia, with isolated 
cranial nerve palsy. Ocular and pulmonary infections are 
the most common extracerebral toxoplasmosis seen in HIV-
infected patients.3 A study by Ammassari and colleagues 
looked at 281 HIV-positive patients with focal neurological 
deﬁ  cits. Toxoplasmic encephalitis was present in 36.4%, 
primary brain lymphoma in 26.7%, progressive multifocal 
leucoencephalopathy in 18.2%, and focal HIV encephalopa-
thy in 5.0%.4
As in our case, up to 97% of patients with CTx have 
toxoplasma IgG antibodies and the levels are usually over 
1:256 in patients with CTx.5 However the level of antibodies 
is not always predictive of the diagnosis as in our patient,6 but 
a negative test makes the diagnosis unlikely. The sensitiv-
ity and speciﬁ  city of Toxoplasma gondii polymerase chain 
reaction (PCR) in blood for the diagnosis of CTx were 80% 
and 98%, respectively.7 Eight out of 19 (42.1%) patients who 
were histologically conﬁ  rmed with CTx had positive PCR in 
the cerebrospinal ﬂ  uid (CSF).8 A negative PCR in the CSF 
will therefore not exclude CTx.9
CT scan typically reveals bilateral, multiple, hypodense 
ring-enhanced lesions with surrounding edema in 70%–80% 
of patients.10 These lesions tend to involve the basal ganglia 
and corticomedullary junctions in either or both hemispheres. 
As in our patient lesions can be solitary in 27% of patients11 
and clinically mistaken for a neoplasm. Magnetic resonance 
imaging scan is more sensitive than CT scan. However 
radiological ﬁ  ndings are not pathognomonic for CTx hence 
stereotactic brain biopsy remains the main stay of diagnosis 
of CTx. Findings range from granulomatous reaction with 
gliosis to necrotising encephalitis. Both free tachyzoites 
and encysted bradyzoites may be found at the periphery of 
the necrotic foci. A study by Gildenberg and colleagues of 
stereotactic brain biopsy in 250 patients revealed patholo-
gies in 246 patients (98%). Multiple pathologies were found 
in 16 (6%) biopsies. Four out of the ﬁ  rst 32 (12%) had 
intracranial bleeding with 3% fatality. After correction of 
coagulopathy, seven out of 218 (3%) developed intracerebral 
bleeding with 2% fatality.12
Increased uptake on thallium-201 single-photon 
emission CT is suggestive of central nervous system (CNS) 
lymphoma. The sensitivity and speciﬁ  city of these ﬁ  ndings 
for the diagnosis of CNS lymphoma range from 86%–100% 
and from 76%–100%, respectively.5 Among primary brain 
tumors, anaplastic astrocytoma and glioblastomas account 
for 38%, and meningiomas account for 27%. Other less 
common primary brain tumors include, in decreasing 
order of frequency, pituitary tumors, schwannomas, 
CNS lymphomas, oligodendrogliomas, ependymomas, 
low-grade astrocytomas, and medulloblastomas.13 Brain 
metastases outnumber primary brain tumors and occur in 
20%–40% of patients with cancer.14 The most common 
cancers causing metastases to the brain are lung cancer 
(50%), breast cancer (15%–20%), unknown primary 
cancer (10%–15%), melanoma (10%), and colon (5%). 
The common sites of metastases occur in cerebral hemi-
spheres (80%), cerebellum (15%), and brain stem (5%).14 
Metastases to the brain are often multiple in more than 
70% of cases, but solitary metastases also occur. Clinical 
features of brain tumors include headache, nausea, vomit-
ing, and personality changes. Another clinical symptom is 
seizures, which occur in 20% of patients with supratentorial 
brain tumors and may antedate many months with slow 
growing brain tumors.15
Our patient was infected with blood-borne viruses 
(Hepatitis B and C) and had a low absolute lymphocyte 
count. A high index of suspicion in those patients with focal 
neurological signs would have prevented unnecessary neuro-
surgical intervention. Empirical antitoxoplasma treatment is 
recommended in HIV-positive patients with ring-enhanced 
lesions with surrounding edema and with positive toxoplasma 
serology. By avoiding the need for brain biopsy, hospital stay International Journal of General Medicine 2009:2 75
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is shortened and subsequently costs are saved.16 Brain biopsy 
should only be considered in patients with negative toxo-
plasma serology and who do not respond to antitoxoplasma 
treatment.17
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Figure 2 Brain biopsy showing numerous tachyzoites.